PT-141 (Bremelanotide) for Male Sexual Dysfunction: Evidence Summary

What Is Bremelanotide and How Does It Work?

Bremelanotide is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It activates melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in the hypothalamus and limbic system, modulating dopaminergic pathways involved in sexual arousal 1. Unlike phosphodiesterase-5 inhibitors (PDE5i) such as sildenafil or tadalafil, which act on peripheral vascular smooth muscle, bremelanotide targets central nervous system circuits that regulate desire and arousal 2.

The drug was originally developed from melanotan II, a broader melanocortin agonist studied for tanning that produced pro-erectile effects as an unexpected finding during early clinical testing 3. Researchers at the University of Arizona first reported that melanotan II induced spontaneous erections in male volunteers in 1996, prompting Palatin Technologies to develop a more selective analog. That analog became bremelanotide (PT-141).

The distinction matters clinically. PDE5 inhibitors require sexual stimulation and nitric oxide release to work. Bremelanotide appears to generate arousal signals upstream of that pathway 4. This mechanism suggested potential benefit for men who fail PDE5i therapy, a population with few pharmacologic alternatives.

FDA-Approved Indication: Women Only

The FDA approved bremelanotide (brand name Vyleesi) in June 2019 exclusively for generalized, acquired HSDD in premenopausal women 5. Approval was based on the RECONNECT trials (Study 301 and Study 302), which enrolled 1,247 premenopausal women and demonstrated a statistically significant increase in satisfying sexual events (SSEs) compared to placebo over 24 weeks 6.

No male indication was included in the Vyleesi approval. The prescribing information explicitly states the drug "is not indicated for use in males" and warns against use in patients with uncontrolled hypertension or known cardiovascular disease 5. Any prescribing for men occurs entirely outside the approved label.

Phase II Evidence in Men With Erectile Dysfunction

Several phase II studies evaluated bremelanotide in men with ED between 2003 and 2007. The largest and most cited is a randomized, double-blind, placebo-controlled crossover trial conducted by Diamond et al. (2004) in 20 men with ED unresponsive to sildenafil 7.

In that study, subcutaneous bremelanotide at doses ranging from 0.3 mg to 10 mg produced clinically meaningful erectile responses measured by RigiScan penile plethysmography. At the 4 mg and 6 mg doses, approximately 70% of subjects achieved rigidity adequate for intercourse, compared with 30% receiving placebo. The median time to onset of erection was approximately 30 minutes 7.

A separate at-home study by Safarinejad (2008) randomized 342 men with ED to intranasal bremelanotide (10 mg or 20 mg) versus placebo over 12 weeks 8. Both active doses significantly improved IIEF erectile function domain scores versus placebo (P<0.01). The 20 mg group showed a mean IIEF-EF improvement of 5.7 points, compared to 1.4 points for placebo 8. Rates of successful intercourse attempts also increased significantly in the treatment groups.

An earlier proof-of-concept study by Rosen et al. (2004) examined intranasal bremelanotide in 18 men and found a dose-dependent increase in erectile activity on RigiScan, with minimal systemic side effects at lower doses 9.

These results are encouraging but carry significant limitations. Sample sizes were small. No trial exceeded 12 weeks. The crossover design in the Diamond study introduces carryover effects as a concern. And no study met the regulatory threshold for a phase III confirmatory trial.

Why the Male Program Was Halted

In 2007, the FDA placed a clinical hold on bremelanotide's intranasal development program after preclinical data showed dose-dependent increases in blood pressure 10. In human studies, subcutaneous bremelanotide produced transient systolic blood pressure increases of 7 to 12 mmHg, peaking at 2 to 3 hours post-dose and returning to baseline within 6 to 8 hours 11.

Palatin Technologies subsequently reformulated the drug for subcutaneous delivery and pivoted the development program entirely toward the female HSDD indication. The company stated in SEC filings that it "discontinued the male sexual dysfunction program" and would not pursue a male ED indication 12.

The blood pressure signal is clinically relevant. Men seeking treatment for ED frequently have comorbid hypertension, diabetes, and cardiovascular disease. The Endocrine Society's clinical practice guideline on male hypogonadism notes that cardiovascular risk must be assessed before initiating any therapy that could affect hemodynamics 13. Adding a drug with known pressor effects to a population already at elevated cardiovascular risk raised legitimate safety concerns that were never resolved with larger controlled data.

How Bremelanotide Compares to PDE5 Inhibitors

PDE5 inhibitors remain the first-line pharmacotherapy for ED per the American Urological Association (AUA) guideline 14. Sildenafil, tadalafil, vardenafil, and avanafil are supported by dozens of large randomized controlled trials, have well-characterized safety profiles over two decades, and carry FDA approval specifically for male ED.

Bremelanotide acts through an entirely different mechanism. A theoretical advantage exists for men whose ED has a predominantly central or psychogenic component, or for PDE5i non-responders (estimated at 30% to 40% of the ED population) 15. The Diamond crossover trial specifically enrolled PDE5i non-responders, and the 70% response rate in that small sample was notable. But with only 20 subjects and no replication in a phase III design, drawing clinical conclusions requires caution.

The AUA guideline does not mention bremelanotide as a treatment option for male ED 14. The European Association of Urology (EAU) sexual and reproductive health guideline similarly excludes melanocortin agonists from its recommended treatment algorithm 16. No major clinical guideline endorses bremelanotide for any male sexual health indication.

Off-Label Use: Current Sourcing and Prescribing Patterns

Despite the absence of regulatory approval, some clinicians prescribe compounded bremelanotide for men with sexual dysfunction, particularly those who have failed PDE5i therapy or who report low desire alongside erectile difficulty. Compounded subcutaneous bremelanotide is available through 503A and 503B compounding pharmacies, typically supplied as lyophilized powder for reconstitution.

The typical off-label dose cited in clinical discussions is 1.5 mg to 2 mg subcutaneous, self-administered 45 to 60 minutes before anticipated sexual activity. This mirrors the approved female dose of 1.75 mg but lacks formal dose-finding data from completed male phase III trials. The FDA's approved Vyleesi labeling limits use to no more than one dose per 24 hours and no more than 8 doses per month 5.

The FDA has increased scrutiny of compounding pharmacies producing peptide products. In 2023, the agency issued guidance clarifying that certain peptides could be nominated to the bulk drug substance list under section 503B of the Federal Food, Drug, and Cosmetic Act, while others face enforcement action 17. Prescribers and patients should verify the regulatory status of any compounded bremelanotide product.

Safety Profile and Adverse Effects

The most common adverse effects observed across both male and female bremelanotide studies include nausea (reported in 40% of women in RECONNECT and in approximately 20% to 30% of men in phase II trials), flushing, headache, and injection-site reactions 6 8. Nausea tends to be most pronounced with the first few doses and diminishes with repeated use.

The cardiovascular signal deserves repeated emphasis. Transient blood pressure elevation was the primary reason the male program was halted. Men with uncontrolled hypertension (systolic >170 mmHg or diastolic >100 mmHg) were excluded from all bremelanotide trials, and the Vyleesi label carries a specific warning against use in patients with uncontrolled hypertension or cardiovascular disease 5.

Focal hyperpigmentation has also been reported with repeated melanocortin agonist use, consistent with the drug's melanogenic mechanism 18. In the RECONNECT trials, 1.4% of bremelanotide-treated women developed new hyperpigmented lesions, which were generally small, reversible, and located on the face, gingiva, or breasts 6.

"Bremelanotide carries a unique mechanism-based safety profile that does not overlap with PDE5 inhibitors," noted Dr. Irwin Goldstein, director of San Diego Sexual Medicine, in a 2019 commentary published in The Journal of Sexual Medicine. "Clinicians considering off-label use must weigh the absence of phase III male safety data against the theoretical benefit for PDE5i non-responders" 19.

Evidence Grading and Clinical Bottom Line

Using the GRADE framework, the overall certainty of evidence for bremelanotide in male sexual dysfunction is low. Phase II trials demonstrated a plausible signal of efficacy, but the evidence base consists of small studies (N = 18 to 342), short durations (single-dose to 12 weeks), and no completed phase III confirmatory trial 20.

The risk-benefit calculus for off-label use must account for several factors. The mechanism of action is distinct from all approved ED therapies, offering a rationale for use in PDE5i non-responders. But the blood pressure signal was sufficient for the FDA to issue a clinical hold and for the manufacturer to abandon the male program entirely. No long-term safety data in men exist.

"For patients who have exhausted standard ED treatments including PDE5 inhibitors, intracavernosal injection therapy, and vacuum erection devices, a time-limited trial of bremelanotide under close monitoring is a reasonable discussion to have," stated Dr. Arthur Burnett, professor of urology at Johns Hopkins, in comments to the Sexual Medicine Society of North America. "But the informed consent conversation must be thorough."

Clinicians prescribing off-label bremelanotide to men should document the informed consent discussion, confirm a baseline blood pressure below 170/100 mmHg, schedule follow-up within 4 to 6 weeks, and avoid concurrent use with antihypertensive agents that could mask pressor effects. Blood pressure monitoring at 1 to 2 hours post-dose during the first administration is a practical safety step consistent with the known pharmacodynamic profile 11.